Teachers Retirement System of The State of Kentucky Makes New $1.08 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM

Teachers Retirement System of The State of Kentucky purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 14,724 shares of the company’s stock, valued at approximately $1,079,000.

Several other institutional investors have also modified their holdings of the business. MCF Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals in the third quarter valued at $33,000. Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. CWM LLC grew its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares in the last quarter. Finally, Osaic Holdings Inc. increased its holdings in Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the period.

Analyst Ratings Changes

A number of research firms have issued reports on MIRM. Royal Bank Of Canada reduced their price target on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Leerink Partners decreased their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Finally, Morgan Stanley boosted their price target on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 1,421 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $132,621.93. Following the transaction, the chief financial officer directly owned 42,127 shares in the company, valued at $3,931,712.91. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joanne Quan sold 6,911 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total transaction of $623,855.97. Following the sale, the insider directly owned 11,305 shares in the company, valued at approximately $1,020,502.35. The trade was a 37.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,136 shares of company stock valued at $4,352,029 over the last three months. 14.36% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ MIRM opened at $86.30 on Friday. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of -179.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The business has a 50-day moving average of $94.25 and a two-hundred day moving average of $79.89. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter in the previous year, the company posted $1.00 EPS. The company’s revenue was up 49.8% compared to the same quarter last year. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.